| Catalog No. | DB885028 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 5.67 ng/mL |
|---|
| Range | 31.25 - 2,000 ng/mL |
|---|
| Accession | P16109 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃. |
|---|
| Specifications | Inclacumab |
|---|
| Alternate Names | LC1004-002, RO4905417, CAS: 1256258-86-2 |
|---|
| Background | Inclacumab is an IgG4 type human monoclonal antibody that inhibits P-selectin, which functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. This drug was developed by Genentech/Roche to reduce the inflammation and heart tissue damage that often occurs during heart surgery when opening up clogged arteries. Global Blood Therapeutics is licensed the drug and plants to investigate the effects of the drug on the vaso-occlusive crisis, a painful complication of sickle cell disease as a complement to its lead investigational oral, voxelotor. |
|---|
| Note | For Research Use Only. |
|---|
